The DEA extended telemedicine prescribing again. Here’s the 2026 map.
Controlled-substance telehealth has run on temporary rules since 2020. The fourth extension buys the industry another year — and the permanent framework is now visible in outline. What to rely on, what expires, and what to build.
Lithos Staff
Photograph via UnsplashDEA/HHS extended the COVID-era telemedicine flexibilities a fourth time, keeping Schedule II–V prescribing via telemedicine lawful through December 31, 2026 — no prior in-person exam required, audio-video for most initial prescribing, state law still governing. The permanent special-registration framework was proposed in January 2025 and remains unfinalized. Programs should operate confidently on today’s rules while building for the registration regime the proposal sketches.
What the fourth extension actually says
Effective January 1, 2026, the DEA and HHS extended the telemedicine flexibilities for prescribing controlled medications through December 31, 2026 — the fourth such extension since the COVID-era rules were due to lapse. The operative effect is unchanged: a DEA-registered practitioner may prescribe Schedule II–V controlled substances to a patient they have never examined in person, provided the encounter happens through real-time telemedicine (audio-video for most initial prescribing), the prescription moves through EPCS, and state law permits the practice.
The extension exists because the permanent framework isn’t ready. The special-registration proposal — published January 2025 — sketches three registration types: a telemedicine prescribing registration for Schedules III–V, an advanced registration for Schedule II prescribing by specialized practitioners, and a platform registration for the companies operating telemedicine platforms that dispense controlled substances. Comment periods closed; the final rule has not issued.
What you can rely on today
| Question | 2026 answer | Basis |
|---|---|---|
| Prescribe II–V via telemedicine? | Yes, where state law allows | Fourth extension, through 2026-12-31 |
| Prior in-person exam required? | No | Suspended by the flexibilities |
| Async controlled prescribing? | Generally no | Real-time encounters expected; states stricter still |
| EPCS required? | Yes | Independent of the flexibilities |
| Permanent rules? | Pending | Special registration proposed, unfinalized |
How to build for the transition
- Operate on today’s rules without apology. The flexibilities are law, not a loophole. Programs meeting them — real-time encounters, EPCS, state compliance, documentation — are compliant programs.
- Build the pieces every future regime requires. Identity-proofed prescribers, certified EPCS, PDMP workflows, and airtight encounter documentation appear in every version of the proposed framework. None of that investment is at risk.
- Map your exposure by branch. Know which patients, states, and products depend on the flexibilities — and what your program does in each January 2027 scenario: final rule, fifth extension, or lapse.
- Watch the platform registration. If the final rule keeps it, DTC platforms touching controlled substances will have their own DEA relationship for the first time — a structural change worth planning for early.
The bottom line
Nothing about 2026 requires waiting: the rules of the road are known through December 31. What the year demands is attention — the special-registration final rule will be the biggest structural change to telehealth prescribing since the Ryan Haight Act, and the programs that read the proposal now will treat it as a catalog update instead of a crisis.
Frequently asked questions
Is telehealth TRT still legal in 2026?
Yes, where state rules allow — testosterone is Schedule III, covered by the extended flexibilities, prescribed via appropriate telemedicine encounters with EPCS. State-by-state modality and PDMP rules still apply.
What happens on January 1, 2027?
Either the special-registration final rule lands, another extension issues, or — the scenario nobody expects but everyone should plan for — the flexibilities lapse back to the in-person rule. Programs should know which patients and products are exposed under each branch.
Do the federal flexibilities override state law?
No. They remove the federal in-person requirement; states still control modality, PDMP checks, and practitioner scope. The stricter rule always wins.
What is the proposed platform registration?
One of three registration types in the January 2025 proposal — a category specifically for telemedicine platforms involved in dispensing controlled substances, alongside prescribing registrations for clinicians. Its final shape will matter to every DTC program with a controlled-substance line.
From first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.